Search results
Results from the WOW.Com Content Network
How expensive is the stock market right now? BioNTech (NASDAQ: BNTX) vaulted into the spotlight in 2020 when Pfizer teamed up with the then-small German company to develop a COVID-19 vaccine.
Price Action: BNTX stock is up 5.87% at $112.57 at the last check on Wednesday. Read Next: Regeneron/Sanofi’s Dupixent Approval Signals Major Treatment Breakthrough For Smokers’ Lung Disease
The stock price has fallen more than 50% in 2024, despite a 10% gain in November. ... However, crunching a few numbers is the best way to explain why BioNTech is a fantastic stock to buy in ...
BioNTech was founded in 2008 based on research by Uğur Şahin, Özlem Türeci, [8] and Christoph Huber, [9] with a seed investment of €180 million [10] from MIG Capital, a Munich-based venture capital firm, the family office of Andreas and Thomas Strüngmann, and the present chairman of the supervisory board, Helmut Jeggle.
Truist initiated with a Buy rating and a price target of $172. BioNTech’s oncology pipeline was previously seen as limited in value outside BNT316. ... Price Action: BNTX stock is up 0.55% at ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Monday, BioNTech SE (NASDAQ:BNTX) reported a first-quarter EPS loss of 1.31 euros ($1.41 loss), a shift from an income of 2.05 euros, missing the consensus loss of 97 cents. The COVID-19 vaccine ...
Monday’s market selloff skipped past BioNTech (BNTX). The German biotech ended the session posting a 12% gain after news that two of the COVID-19 vaccine candidates it is co-developing with ...